Rchr
J-GLOBAL ID：201801019371273809   Update date: Jan. 30, 2024

Onishi Nobuyuki

オオニシ ノブユキ | Onishi Nobuyuki
Affiliation and department：
Showa University Dept. of Clin. Diag Oncol., Clin. Res. Inst. for Clin. Pharmacol. and Ther.

About Showa University Dept. of Clin. Diag Oncol., Clin. Res. Inst. for Clin. Pharmacol. and Ther.


Other affiliations (1)：
  • Keio University  School of Medicine Department of Plastic and Reconstructive Surgery 
Research field  (3)： Molecular biology ,  Laboratory animal science ,  Tumor biology
Research theme for competitive and other funds  (5)：
  • 2019 - 2022 Development of easy-to-use genome editing protein synthesis system and one-step genetically modified animal production method
  • 2016 - 2019 Development of novel mouse brain tumor model using in vivo electroporation and piggyBac system
  • 2013 - 2015 Development of recurrence mouse brain tumor model using inducible iCSCs and identification of target molecules in recurrence tumor
  • 2010 - 2011 Establishment of human induced cancer stem cells(iCSCs) and malignant brain tumor models derived from neural stem cells
  • 2005 - 2007 DNA損傷応答におけるWip1による細胞周期チェックポイントの解除機構
Papers (61)：
  • Ryotaro Ohkuma, Sakiko Miura, Satoshi Muto, Yoshitaka Toyomasu, Yuki Fujimoto, Katsuaki Ieguchi, Nobuyuki Onishi, Takashi Shimizu, Makoto Watanabe, Daisuke Takayanagi, et al. Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors. Frontiers in immunology. 2023. 18. 14. 1260492-1260492
  • Ryotaro Ohkuma, Yuki Fujimoto, Katsuaki Ieguchi, Nobuyuki Onishi, Makoto Watanabe, Daisuke Takayanagi, Tsubasa Goshima, Atsushi Horiike, Kazuyuki Hamada, Hirotsugu Ariizumi, Yuya Hirasawa, Tomoyuki Ishiguro, Risako Suzuki, Nana Iriguchi, Toshiaki Tsurui, Yosuke Sasaki, Mayumi Homma, Toshiko Yamochi, Kiyoshi Yoshimura, Mayumi Tsuji, Yuji Kiuchi, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada. Monocyte subsets associated with the efficacy of anti-PD-1 antibody monotherapy. Oncol Lett. 2023. 26. 3. 381-381
  • 信末 博行, 清水 孝恒, 高橋 信博, 山口 さやか, 杉原 英志, 大西 伸幸, 佐谷 秀行. MKL1の阻害は化学療法抵抗性骨肉腫細胞において抗がん剤の抗腫瘍効果を増強する(Inhibition of MKL1 enhances the effects of anticancer drugs in chemoresistant osteosarcoma cells). 日本癌学会総会記事. 2022. 81回. J-1026
  • Kazuhide Miyamoto, Hodaka Hayabuchi, Yukiko Tokifuji, Makoto Ando, Nobuyuki Onishi, Tadashi Okamuara, Akihiko Yoshimura, Shunsuke Chikuma. A Protein Kinase D Inhibitor Suppresses AKT on T cells and Antagonizes Cancer Immunotherapy by Anti-PD-1. International immunology. 2022. 34. 12. 609-619
  • Megumi Uetaki, Nobuyuki Onishi, Yoshinao Oki, Takatsune Shimizu, Eiji Sugihara, Oltea Sampetrean, Takashi Watanabe, Hisano Yanagi, Kiyoshi Suda, Hiroya Fujii, et al. Regulatory roles of fibronectin and integrin α5 in reorganization of the actin cytoskeleton and completion of adipogenesis. Molecular biology of the cell. 2022. 33. 9. mbcE21120609
ｍore...
MISC (32)：
ｍore...
Education (2)：
  • 2002 - 2008 Kobe University
  • 1998 - 2002 Kindai University Faculty of Science and Engineering
Professional career (1)：
  • 博士(医学) (神戸大学)
Work history (9)：
  • 2022/10 - 現在 Keio University School of Medicine Department of Plastic and Reconstructive Surgery
  • 2022/05 - 現在 Showa University Dept. of Clin. Diag Oncol., Clin. Res. Inst. for Clin. Pharmacol. and Ther.
  • 2022/05 - 2022/09 Keio University School of Medicine Department of Plastic and Reconstructive Surgery
  • 2022/04 - 2022/04 Keio University School of Medicine Department of Plastic and Reconstructive Surgery
  • 2017/04 - 2022/03 株式会社 島津製作所 基盤技術研究所 嘱託研究員
Show all
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM